McCaffreyJ., et al., High-throughput single-molecule telomere characterization. Genome Res, 2017. 27(11): p. 1904–1915.
2.
ShayJ.W. and WrightW.E., Telomeres and telomerase: three decades of progress. Nat Rev Genet, 2019. 20(5): p. 299–309.
3.
ChakravartiD. and DePinhoR.A., Telomere Dysfunction as an Initiator of Inflamma tion: Clues to an Age-Old Mystery. J Inflamm Bowel Dis Disord, 2021. 6(2).
4.
KimN.W., et al., Specific association of human telomerase activity with immortal cells and cancer. Science, 1994. 266(5193): p. 2011–5.
5.
ShayJ.W. and BacchettiS., A survey of telomerase activity in human cancer. Eur J Cancer, 1997. 33(5): p. 787–91.
6.
BryanT.M., et al., Evidence for an alternative mechanism for maintaining telomere length in human tumors and tumor-derived cell lines. Nat Med, 1997. 3(11): p. 1271–4.
7.
NguyenK. and WongJ.M.Y., Telomerase Biogenesis and Activities from the Per spec tive of Its Direct Interacting Partners. Cancers (Basel), 2020. 12(6).
8.
WuR.A., et al., Telomerase Mechanism of Telomere Synthesis. Annu Rev Biochem, 2017. 86: p. 439-460.
9.
XuY. and GoldkornA., Telomere and Telomerase Therapeutics in Cancer. Genes (Basel), 2016. 7(6).
10.
HuJ., et al., Antitelomerase therapy provokes ALT and mitochondrial adaptive mech anisms in cancer. Cell, 2012. 148(4): p. 651–63.
11.
MacKenzieD.Jr., et al., ALT Positivity in Human Cancers: Prevalence and Clinical Insights. Cancers (Basel), 2021. 13(10).
12.
SobinoffA.P. and PickettH.A., Mechanisms that drive telomere maintenance and recombination in human cancers. Curr Opin Genet Dev, 2020. 60: p. 25-30.
13.
ZhangJ.M. and ZouL., Alternative lengthening of telomeres: from molecular mecha nisms to therapeutic outlooks. Cell Biosci, 2020. 10: p. 30.
14.
LuR. and PickettH.A., Telomeric replication stress: the beginning and the end for alternative lengthening of telomeres cancers. Open Biol, 2022. 12(3): p. 220011.
15.
PanX., et al., Breaking the end: Target the replication stress response at the ALT telomeres for cancer therapy. Mol Cell Oncol, 2017. 4(6): p. e1360978.
16.
WhitbyM.C., The FANCM family of DNA helicases/translocases. DNA Repair (Amst), 2010. 9(3): p. 224–36.
17.
XueX., SungP., and ZhaoX., Functions and regulation of the multitasking FANCM family of DNA motor proteins. Genes Dev, 2015. 29(17): p. 1777–88.
18.
PanX., et al., FANCM, BRCA1, and BLM cooperatively resolve the replication stress at the ALT telomeres. Proc Natl Acad Sci U S A, 2017. 114(29): p. E5940–E5949.
19.
SilvaB., et al., FANCM limits ALT activity by restricting telomeric replication stress induced by deregulated BLM and R-loops. Nat Commun, 2019. 10(1): p. 2253.
20.
LuR., et al., The FANCM-BLM-TOP3A-RMI complex suppresses alternative length ening of telomeres (ALT). Nat Commun, 2019. 10(1): p. 2252.
21.
WangH., et al., BLM prevents instability of structure-forming DNA sequences at common fragile sites. PLoS Genet, 2018. 14(11): p. e1007816.
22.
PandayA., et al., FANCM regulates repair pathway choice at stalled replication forks. Mol Cell, 2021. 81(11): p. 2428–2444 e6.
23.
FlynnR.L., et al., Alternative lengthening of telomeres renders cancer cells hyper sensitive to ATR inhibitors. Science, 2015. 347(6219): p. 273–7.
24.
HeaphyC.M., et al., Prevalence of the alternative lengthening of telomeres tel omere maintenance mechanism in human cancer subtypes. Am J Pathol, 2011. 179(4): p. 1608–15.
25.
HensonJ.D., et al., DNA C-circles are specific and quantifiable markers of alterna tive-lengthening-of-telomeres activity. Nat Biotechnol, 2009. 27(12): p. 1181–5.
26.
IdilliA.I., et al., A C-circle assay for detection of alternative lengthening of tel omere activity in FFPE tissue. STAR Protoc, 2021. 2(2): p. 100569.
27.
ChenY.Y., et al., The C-Circle Biomarker Is Secreted by Alternative-Lengthen ing-of-Telomeres Positive Cancer Cells inside Exosomes and Provides a Blood-Based Diagnostic for ALT Activity. Cancers (Basel), 2021. 13(21).
